OUR Mission

Nour Heart is a Connecticut-based biomedical company aimed at developing diagnostic and therapeutic products for the early detection, prevention, and treatment of myocardial ischemia in patients with ischemic heart disease.

OUR Goals

Nour Heart is currently developing and commercializing for human use its innovative and patented technologies related to Nourin molecular biomarkers for myocardial ischemia and the cardioprotective, Cyclocreatine Phosphate.

OUR Products

Novel Diagnostic Blood-Based Test

Nourin®miRNAs: Novel Molecular Biomarkers for Early Identification or Exclusion of Myocardial Ischemia in Women Suspected of Having Coronary Artery Disease (CAD) before Progression to Infarction (Necrosis).

Read More ...
Novel Bioenergetic Preventive Therapy

Cyclocreatine Phosphate (CCrP): A Novel Preventive Therapy to Protect Hearts Against Ischemic Injury and Retore Cardiac Function with Clinical Applications in Heart Transplantation, Cardiac Surgery, and Interventional Cardiology.

Read More ...

Nour Heart, Inc.

Dr. Elgebaly is a Cardio Pharmacologist who founded Nour Heart, Inc. in Hartford, Connecticut, U.S. and she is the Company’s Chief Executive Officer (CEO). The Company’s mission is to develop and commercialize diagnostic and therapeutic products for the early detection, prevention, and treatment of myocardial ischemia in patients with ischemic heart disease. She is a former Associate Professor and Director of Surgical Research at the Department of Surgery, University of Connecticut School of Medicine, Farmington, Connecticut, U.S. Currently Dr. Elgebaly holds an adjunct faculty position at the Department of Surgery, University of Connecticut School of Medicine.

Read More
Professor Dr. Salwa Ahmed Elgebaly
Founder & CEO

Our Team

Our team has extensive experience in drug development and commercialization according to USFDA regulations. Nour Heart’s team includes cardiac pharmacologists, cardiac surgeon, transplant surgeon, intervention cardiologist, non-invasive cardiologist, experts in cardiac biomarkers (protein and molecular), drug process chemistry, formulation, and manufacturing according to FDA Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP), as well as extensive expertise in Active Pharmaceutical Ingredient (API) and finished product manufacturing, validation, Quality Assurance (QA), Investigational New Drug (IND) application and New Drug Application (NDA) filings to the USFDA.

Read More
Copyright @ Nour Heart 2022
Powered By : Idea World Web